HOLON, Israel, Feb. 18,
2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN) a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced, that it
will release its fourth quarter and full year 2024 financial
results on Tuesday, March 4, 2025,
before the U.S. financial markets open. Management will host
a conference call and webcast to review the financial results and
provide a corporate update at 8:30 am
ET.
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S., or +972-3-918-0644
internationally. The call will be available via live webcast
through Compugen's website, located at the following link.
Following the live webcast, a replay will be available on the
Company's website.
About Compugen
Compugen is a
clinical-stage therapeutic discovery and development company
utilizing its broadly applicable predictive computational discovery
platform (Unigen™) to identify new drug targets and
biological pathways for developing cancer
immunotherapies. Compugen has two proprietary
product candidates in Phase 1 development: COM701, a potential
first-in-class anti-PVRIG antibody and COM902, a
potential best-in-class antibody targeting TIGIT for
the treatment of solid tumors. Rilvegostomig, a
PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical
stage anti-TIGIT antibody, COM902, is in Phase 3
development by AstraZeneca through a license agreement
for the development of bispecific and
multispecific antibodies. GS-0321 (previously COM503), a
potential first-in-class, high affinity anti-IL-18 binding protein
antibody, which is in Phase 1 development is licensed to
Gilead. In addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of
programs aiming to address various mechanisms of immune
resistance. Compugen is headquartered in
Israel, with offices in
San Francisco, CA.
Compugen's shares are listed on Nasdaq and the
Tel Aviv Stock Exchange under the ticker symbol
CGEN.
Company contact:
Yvonne
Naughton, Ph.D.
VP, Head of
Investor Relations, and Corporate
Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2024-financial-results-on-tuesday-march-4-2025-302378746.html
SOURCE Compugen Ltd.